Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?

Neuro Oncol. 2018 Jul 5;20(8):1144. doi: 10.1093/neuonc/noy092.

Authors

Eudocia Quant Lee¹, J Ricardo McFaline-Figueroa¹, Timothy F Cloughesy², Patrick Y Wen¹

Affiliations

¹ Center for Neuro-Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts.
² Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

No abstract available

MeSH terms

Blood-Brain Barrier / drug effects
Blood-Brain Barrier / pathology*
Brain Neoplasms / drug therapy*
Brain Neoplasms / pathology
Glioma / drug therapy*
Glioma / pathology
Humans
Irinotecan / therapeutic use*
Neoplasm Grading
Topoisomerase I Inhibitors / therapeutic use*
Treatment Outcome

Substances

Topoisomerase I Inhibitors
Irinotecan

Grants and funding

P50 CA211015/CA/NCI NIH HHS/United States